Compare YELP & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | HRMY |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2011 | 2020 |
| Metric | YELP | HRMY |
|---|---|---|
| Price | $25.46 | $28.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $29.17 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 1.1M | 609.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | 7.97 |
| EPS | 2.24 | ★ 2.71 |
| Revenue | ★ $1,464,955,000.00 | $868,453,000.00 |
| Revenue This Year | $2.19 | $19.75 |
| Revenue Next Year | $2.54 | $12.88 |
| P/E Ratio | $11.41 | ★ $10.78 |
| Revenue Growth | 3.75 | ★ 21.51 |
| 52 Week Low | $19.60 | $25.52 |
| 52 Week High | $40.25 | $40.87 |
| Indicator | YELP | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 52.88 |
| Support Level | $23.50 | $25.92 |
| Resistance Level | $30.75 | $30.96 |
| Average True Range (ATR) | 0.77 | 0.80 |
| MACD | 0.09 | 0.41 |
| Stochastic Oscillator | 67.95 | 83.86 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.